Australian High Court hears high-stakes matter of PTE eligibility of formulation patents By Dr Claire Gregg on Wednesday, June 17, 2026 #patents Australia Claire Gregg formulation patents OzKat patent term extension +
Otsuka seeks to appeal decision to deny PTEs for formulation patents in Australia By Dr Claire Gregg on Monday, March 02, 2026 Australia Claire Gregg formulation patents OzKat patent term extension +
Formulation patents no longer eligible for PTE in Australia By Dr Claire Gregg on Saturday, December 06, 2025 Australia Claire Gregg formulation patents OzKat patent term extension PTE +
When your formulation IP is beyond compare (T 0722/24) By Dr Rose Hughes on Monday, August 25, 2025 epo formulation patents inventive step obvious to try patents PatKat Rose Hughes +
No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) By Dr Rose Hughes on Tuesday, April 22, 2025 formulation patents G 1/24 ip strategy patents PatKat Rose Hughes us patents +
BREAKING: Supreme Court confirms no hard line on inventive step test in finding Cialis dosage patent obvious By Dr Rose Hughes on Wednesday, March 27, 2019 actavis Court of Appeal dosage dosage regime patents formulation patents obviousness patents priority reasonable expectation of success Second medical use +
The rise of "obvious to try" is over as Court of Appeal finds CIALIS dosage regimen patent obvious By Annsley Merelle Ward on Sunday, November 05, 2017 actavis AmeriKat burden of proof Court of Appeal dosage dosage regime patents formulation patents obviousness priority reasonable expectation of success Teva +
UPDATE: Birss J refuses permission to appeal in Genentech's Herceptin battle By Annsley Merelle Ward on Friday, May 23, 2014 AmeriKat appeal dosage regime patents formulation patents Genentech Hospira interim costs mr justice birss revocation +